期刊文献+

不同辅助治疗方法对Ⅰb~Ⅱa期子宫颈癌术后有危险因素患者预后的影响 被引量:16

Results of different postoperative adjuvant therapies for stage I b - II a cervical carcinoma with risk factors
原文传递
导出
摘要 目的探讨不同的辅助治疗方法对Ⅰb~Ⅱa期子宫颈癌术后有危险因素患者预后的影响。方法白1995年3月至2010年6月,在北京大学第一医院妇产科行手术治疗,且术后有危险因素并进一步行辅助化疗(化疗组,79例)、放疗或放化疗联合治疗(放化疗组,58例)的Ⅰb~Ⅱa期子宫颈癌患者共137例,两组患者均行子宫广泛性切除+盆腔淋巴结切除术。术后危险因素分为中危冈素(包括肿瘤直径〉4cm、脉管癌栓、浸润问质深层)和高危因素(包括宫旁转移、淋巴结转移和切缘阳性)。同颐性分析两组患者的临床病理特征;用Kaplan—Meier法计算并比较两组患者的5年生存率;对影响患者预后的因素进行分析,单因素分析采用log—rank检验,多因素分析采用Cox逐步回归法。结果化疗组与放化疗组患者的年龄、新辅助化疗、临床分期、病理类型、病理分化程度、肿瘤直径、问质浸润深度、宫旁转移分别比较,差异均无统计学意义(P〉0.05);而两组患者的术后危险因素程度、脉管癌栓、淋巴结转移分别比较,差异则有统计学意义(P〈0.05)。化疗组、放化疗组患者的5年生存率分别为88.6%、89.7%,两组比较,差异无统计学意义(P=0.455)。单因素分析显示,病理类型、术后危险因素程度、高危因素个数、宫旁转移、淋巴结转移与患者的预后有关(P〈0.05);多因素分析最示,临床分期、病理类型、术后危险因素程度是影响患者预后的独立因素(P〈0.05)。进一步对术后具有不同程度危险因素的子宫颈癌患者分别给予不同方式的辅助治疗后的预后进行分析,结果显示,在43例有术后高危因素的患者中,给予化疗、放化疗患者(分别为18、25例)的5年生存率分别为77.8%、80.0%,3年无瘤生存率分别为100.0%、80.0%,分别比较,差异均无统计学意义(P=0.316,P=0.172);在94例有术后中危因素的患者中,给予化疗、放化疗患者(分别为61、33例)的5年生存率分别为91.8%、97.0%,3年无瘤生存率分别为98.4%、97.0%,分别比较,差异也均无统计学意义(P=0.220,P=0.549)。结论Ⅰb~Ⅱa期子宫颈癌术后有危险因素的患者,采用化疗可能达到与放疗或放化疗联合治疗相似的治疗效果,化疗可作为这些患者术后辅助治疗的选择之一。, Objective To investigate the effects of postoperative adjuvant chemotherapy (CT) and chemoradiotherapy (CRT) or radiotherapy(RT) for I b- I[ a cervical cancer with risk faetors. Methods From March 1995 to June 2010, there were 137 patients underwent radical hysterectomy and systematic pelvic lymphadenectomy for stage I b - 11 a cervical cancer admitted at Peking University First Hospital. These patients had risk factors, intermediate risk factors including bulky tumor ( 〉4 cm) , lymph vascular space invasion, deep stromal invasion; high risk factors including positive surgical margin, parametrial invasion, lymph node involvement. Of the all patients, 79 cases of them were treated with CT,58 of them were treated with RT or CRT. The 5-year survival and prognosis factors were analyzed retrospectively, the prognosis was compared between two adjuvant therapy groups. Results The univariate analysis shown that types of pathology, different grade of risk factors, stroma invasion and lymph node involvement were prognostic factors of 5-year overall survival. Patients with squamous cell carcinoma, intermediate risk factors, no parametrial invasion, and no lymph node involvement had better prognosis (P 〈 0.05 ). Whether patients with high-risk factors or intermediate-risk factors, the 5-year overall survival and 3-year disease-free survival had no difference between CT and RCT or RT groups respectively. Cox regression multivariate analysis of survival indicated that clinical stages, types of histology, different grade of risk factors were independent prognostic indicator. Patients with early stage, squamous cell carcinoma, intermediate risk factors had better prognosis. Univariate and multivariate analysis indicated that different postoperative adjuvant therapies had no effects on the prognosis. The 5-year overall survival was 88.6% in patients treated with CT, and 89. 7% in patients treated with RT or CRT (P = 0. 455 ). Conclusion There are equivalent therapeutic results between CT and RT or CRT for patients with risk factors after radical surgery, CT may be as one choice of postoperative adjuvant therapy for stage I b - ]I a cervical carcinoma with risk factors.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2013年第12期920-924,共5页 Chinese Journal of Obstetrics and Gynecology
关键词 宫颈肿瘤 化学疗法 辅助 放射疗法 预后 Uterine cervical neoplasms Chemotherapy, adjuvant Radiotherapy Prognosis
  • 相关文献

参考文献11

  • 1Park JY, Kim DY, Kim JH, et al. Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer. Ann Oncol,2011,22:59-67.
  • 2Song S, Song C, Kim H J, et al. 20 yezr experience of postoperative radiotherapy in I B-II A cervical cancer patients with intermediate risk factor:s: impact of treatment period and concurrent chemotherapy. Gyneeol Oncol,2012,124:63457.
  • 3Garg G, Shah JP, Toy EP, et al. Stage II A1 versus stage II A2 cervical cancer: does the new staging criteria predict survival? . Int J Gynecol Cancer,2011,21:711-716.
  • 4Mot V, Laliberte L, Morris JN, et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer,1984,53:2002-2007.
  • 5张国楠,宋水勤.宫颈癌动脉化疗进展[J].实用妇产科杂志,2006,22(8):458-460. 被引量:23
  • 6Benedet JL, Bender H, Jones H 3rd, et ah FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet,2000,70:209-262.
  • 7Koh WJ, Greer BE, Abu-Rustum NR, et al. Cervical cancer. J Natl Compr Canc Netw,2013,11:320-343.
  • 8Rosa DD, Medeiros LR, Edelweiss MI, et al. Adjuvant platinum- based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev,2012,6 : CD005342.
  • 9Hosaka M, Watari H, Takeda M, et al. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymphadenectomy. J Obstet Gynaecol Res,2008 ,34 :552-556.
  • 10Lee KB, Lee JM, Ki KD, et al. Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage I B-II A cervical cancer. Int J Gynecol Cancer,2008,18 : 1027-1031.

共引文献22

同被引文献129

  • 1周克水,朱华,鲁玮.腹腔镜下广泛子宫切除加盆腔淋巴结清扫术(附30例报告)[J].腹腔镜外科杂志,2006,11(1):10-11. 被引量:6
  • 2孟元光,李亚里,宋磊,彭红梅,李秀丽,李立安,黄柯,王玉峰.腹腔镜手术治疗40例宫颈癌患者的临床病例分析[J].中国肿瘤临床,2007,34(13):764-766. 被引量:4
  • 3Hossein R, Behzad S, Tahar M, et al. Prevalence of human papillomavirus genotypes associated with cervical and breast cancer iniran [ J]. Monoclon Antib Immuno- diagn Immunother, 2013,32(6) :399 -403.
  • 4Arbyn M, Ronco G, Anttila A, et al. Evidence regard- ing human papillomavirus testing in secondary prevention of cervical cancer [ J ]. Vaccine, 2012, 30 ( 5 ) : 88 - 99.
  • 5Vandecasteele K, Makar A, Vanden Broecke R, et al. Intensity-modulated arc therapy with clsplatin as neo- adjuvant treatment for primary irresectable cervical canc- er Toxicity, tumour response and outcome [ J]. Strahl- entherapie und Onkologie, 2012,188 (7) :576 - 581.
  • 6Bendetti Panici P, Greggi S, Colombo A, et al. Neoadju- vant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian muhicenter randomized study [ J]. Journal of Clinical Oncology,2001,17 (20) : 179 - 188.
  • 7Neoadjuvant Chemotherapy for locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chem- otherapy for locally advanced cervical cancer: a systemat- ic review and recta-analysis of individual patient data from 21 randomized trials [ J ]. European Journal of Cancer,2003,39( 17 ) :2470 - 2486.
  • 8Benedetti Panici P, Bellati F, Pastore M, et al. An up- date in neoadjuvant chemotherapy in cervical cancer [ J ]. Gynecologic Oncology, 2007,107 ( 1Sll ) :20 - 22.
  • 9Xia X,Xu H, Wang Z, et al. Analysis of prognostic factors affecting the outcome of stage I B - II B cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy. Am J Clin Oncol,2014 Jun 16. [ Epub ahead of print].
  • 10Lee TY, Jeung Y J, Lee C J, et al. Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage IB cervical cancer. Obstet Gynecol Sci,2013, 56(1) :15 -21.

引证文献16

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部